By admin 
After experiencing a surge to record levels in 2024, venture capital investments in women’s health companies faced a significant downturn last year, reflecting a broader recalibration within the healthcare investment landscape. Industry observers suggest that this shift, coupled with evolving marketing strategies by entrepreneurs and startups, could pave the way for a more sustainable rebound in the burgeoning sector. The dramatic decline underscores a pivotal moment for "femtech" and other innovators targeting women-specific health needs, pushing them to demonstrate greater tangible traction and broaden their market appeal to secure crucial early-stage funding.
The context of this downturn is illuminated by a recent report from Silicon Valley Bank (SVB), a division of First Citizens Bank renowned for tracking startup funding trends. According to SVB’s comprehensive analysis, the total venture funding allocated to women’s health companies—encompassing developers of therapeutics, medical devices, and health technologies—plummeted from an impressive $3.2 billion in 2024 to approximately $2 billion in 2025. This substantial 37.5% reduction in capital inflows was mirrored by a contraction in the proportion of healthcare venture deals involving these companies, which fell from 7.4% to 5.7% over the same period. This data signals a marked shift in investor sentiment and capital allocation priorities.
The Broader Healthcare Investment Reset
The authors of the SVB report contend that the deceleration in women’s health funding is not an isolated phenomenon but rather a component of a larger transformation sweeping across the entire healthcare ecosystem. Investors, increasingly risk-averse in a volatile economic climate, have redirected their focus towards more established companies perceived as safer bets, offering clearer paths to commercialization and returns. This strategic pivot reflects a widespread trend in venture capital, where the exuberance of previous years has given way to a more conservative, outcomes-driven approach. Megan Scheffel, head of life sciences and healthcare for SVB, articulated this shift in an interview with BioPharma Dive, stating, "There’s a shift in healthcare investing as a whole."
This "reset," as Scheffel terms it, is fundamentally recalibrating how and where capital flows through the market. For nascent women’s health startups, the ripple effects are profound. Young companies are now compelled to demonstrate significantly more progress and proof of concept than was previously required to secure initial funding. Founders must achieve "tangible early traction," a higher bar that fewer companies are currently meeting. Consequently, fewer startups are successfully advancing to subsequent funding rounds, and investors are deploying smaller amounts into earlier-stage companies. Scheffel observed, "While initial capital remains available, the baseline to secure it has shifted dramatically. Progress that used to be the province of Series A is now required to raise a Seed round." This exigency means companies are "doing more with less," navigating a landscape where fundraising is tougher and valuations are adjusted downwards.
Biopharma’s Particular Headwinds
Within the women’s health sector, biopharma startups experienced an especially harsh impact. Venture funding for these companies plunged from $1.3 billion to a mere $610 million, as detailed in the SVB report. This dramatic decrease highlights the inherent challenges and longer development timelines associated with drug discovery and development, making biopharma ventures inherently riskier and requiring more substantial, sustained capital. The shift towards established companies and the demand for quicker returns further exacerbate the difficulties for early-stage biopharma innovators in women’s health.
Adding another layer of complexity is the intense competition from AI-centric startups, which, according to Payal Divakaran of investment firm .406 Ventures, are "sucking up a lot of the air in the room." Investments in AI drug discovery and other artificial intelligence applications within healthcare are significantly boosting overall venture funding totals in the biopharmaceutical space. However, women’s health companies have not yet fully capitalized on this AI trend in the same way as other segments of the healthcare industry, potentially leaving them at a disadvantage in the race for investor attention and capital. The perception of AI’s transformative power in healthcare, while generally high among investors, has not yet translated into a proportionate influx of funds for women’s health innovations that integrate AI.
Evolving Marketing Strategies: Broadening the Scope of Women’s Health
In response to these market pressures and investor preferences, women’s health companies are strategically re-evaluating and altering their investment pitches. Historically, when SVB’s team first began tracking women’s health investments a few years ago, venture deals were predominantly concentrated on reproductive healthcare, a term encompassing contraception, maternal health issues, and fertility solutions. While crucial, this focus often presented "difficult investment propositions" due to historically underfunded drug development in these areas and longstanding research gaps, as highlighted by organizations like the American College of Obstetricians and Gynecologists (ACOG).
Douglas Tsao, a senior analyst and managing director at investment firm H.C. Wainwright, notes that "Women’s health is a category that, to some extent, has been out of favor with traditional biotech investors." This sentiment has been reinforced by the commercial performance of some recent drug products specifically tailored for women. For instance, Veozah, a non-hormonal therapy developed by Astellas Pharma for menopause, struggled to gain significant market traction following its 2023 launch due to a combination of lower-than-anticipated demand and reimbursement hurdles. Despite reaching approximately $300 million in sales last year and nearly $100 million in the first fiscal quarter of 2026, its initial trajectory was slower than expected. Similarly, Bayer’s competing drug, Lynkuet, approved last year, has yet to have its sales publicly broken out, indicating potential similar challenges. These commercial setbacks contribute to investor hesitancy in a sector already perceived as niche.
Recognizing these dynamics, women’s health companies are now actively expanding their "addressable market" in their pitches. Instead of solely focusing on conditions exclusive to women, they are increasingly highlighting how their innovations address broader health issues—such as depression, obesity, or heart disease—that affect both men and women but impact women differently, disproportionately, or uniquely. This subtle yet significant shift in narrative aims to attract a wider pool of investors who might be wary of perceived niche markets. Scheffel explains, "People don’t come out and say I’m serving women, because they’re not only serving women, they’re serving men and women. It’s like a marketing issue more than it is anything else." By framing their solutions within a larger market context, these companies aim to demonstrate greater commercial viability and broader applicability, thereby appealing to a more diverse investor base.
Signs of Resilience: M&A, IPOs, and Unicorns
Despite the overall decline in venture funding, the women’s health sector has shown notable signs of resilience and maturation in other areas of the capital market. SVB’s report pointed out that 18 women’s health companies were acquired in 2025, a slight dip from 21 purchases in the preceding year, but still indicative of healthy M&A activity. In a particularly active year for biopharmaceutical dealmaking in 2026, one of the largest buyouts involved a prominent women’s health company, Organon, underscoring the strategic value some larger players see in this domain.
Furthermore, the public markets offered a glimmer of hope. In 2025, 14 women’s health startups successfully went public, a significant rebound from zero IPOs recorded in 2024. This suggests that while early-stage venture funding became more challenging, mature companies with robust pipelines or established products found opportunities to access public capital. The emergence of "unicorns"—companies valued at a billion dollars or more—such as Flo Health, Midi Health, and Maven, further validates the long-term potential and market demand within the women’s health space. These success stories provide compelling evidence that, despite the headwinds, significant value can be created and realized.
Tsao of H.C. Wainwright observes that much of this successful activity, particularly in terms of quicker market entry and commercialization, is concentrated around "low barrier to entry" aspects of women’s health. This includes diagnostics or testing services, which typically require less capital and shorter development cycles compared to novel medicines. These segments offer a more immediate path to revenue and scalability, making them attractive targets for both investors and acquirers seeking quicker returns.
The Promise of Data and AI Integration
Looking ahead, the integration of artificial intelligence presents a significant opportunity for women’s health companies to accelerate investment and unlock new therapeutic avenues. While a Pew Research Center poll cited in SVB’s report indicated that women are less likely than men to believe AI can improve their healthcare, the underlying potential remains immense. Scheffel highlights that many women’s health companies are meticulously compiling vast troves of data on women across various life stages, including pregnancy and menopause. This rich, longitudinal data, often unique to the female physiology and health journey, could be invaluable.
By leveraging AI and advanced analytics, this data could be mined to unearth novel insights, identify previously unrecognized biomarkers, and accelerate the discovery and development of future treatments for a multitude of underserved conditions. Conditions like Polycystic Ovary Syndrome (PCOS) and endometriosis, which profoundly impact millions of women globally and have historically suffered from under-representation in clinical trials and research, stand to benefit immensely from AI-driven data analysis. The ability of AI to process complex biological and clinical data at scale could pinpoint new drug targets, personalize treatment protocols, and optimize clinical trial designs, thereby addressing the persistent research gaps that have plagued women’s health for decades.
Scheffel firmly believes in this transformative potential, stating, "There’s a pretty big opportunity for change." The convergence of increasing data availability, advancements in AI capabilities, and a renewed strategic focus by women’s health innovators on broader, data-driven solutions could indeed spark a more resilient and sustainable growth trajectory for the sector. As companies navigate the current "reset," those that effectively integrate AI, broaden their market appeal, and demonstrate tangible early traction are best positioned to attract capital and drive meaningful innovation in women’s health. The current market recalibration, while challenging, ultimately serves as a crucible, forging a more robust and strategically aligned industry poised for long-term impact.
